Cancer genome characterization has recently revealed recurrent missense mutations in the Speckle-type POZ protein (SPOP) gene in 11–13% of primary prostate cancer (PCa)1,2 and to a less 6–8% in metastatic, castration-resistant prostate cancers (CRPC)3,4. The gene discussed is SPOP; the disease is cancer.